ArticleHuman gene therapy2015

Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.

Paul E Monahan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.